Enliven Therapeutics, Inc. · NASDAQ:ELVN
Hohl Benjamin sold 6,018 Enliven Therapeutics, Inc. shares (Form 4)
Traded Jun 17, 2026 · Filed Jun 22, 2026
On Jun 17, 2026, Hohl Benjamin (CHIEF FINANCIAL OFFICER) sold 6,018 Enliven Therapeutics, Inc. shares at an average US$43.80 for US$264K under a trading plan, leaving 51,000 shares. Filed Jun 22, 2026 (Form 4).
- Sold
- 6,018 shares
- Price
- US$43.80 average (US$42.79 to US$44.75)
- Value
- US$264K
- Holding after
- 51,000 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- CHIEF FINANCIAL OFFICER
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Jun 17, 2026 | Common Stock | Option exercise | 6,018 | US$2.48 | 57,018 | Direct |
| Jun 17, 2026 | Common Stock | Sale | 1,379 | US$42.79 | 55,639 | Direct |
| Jun 17, 2026 | Common Stock | Sale | 3,401 | US$43.86 | 52,238 | Direct |
| Jun 17, 2026 | Common Stock | Sale | 1,238 | US$44.75 | 51,000 | Direct |
Source
Related
- Enliven Therapeutics, Inc.
- Hohl Benjamin
- Enliven Therapeutics, Inc. shareholders
- Form 4 · Hohl Benjamin · Sep 21, 2026
- Form 4 · Hohl Benjamin · Aug 19, 2026
- Form 4 · Hohl Benjamin · Jul 21, 2026
- Form 4 · Garland J. Scott · Oct 5, 2026
- Form 4 · Collins Helen Louise · Sep 21, 2026
- Form 4 · Collins Helen Louise · Aug 19, 2026
- Form 4 · Derynck Mika K · Aug 6, 2026
- Schedule 13G/A · FMR LLC · Aug 6, 2026